A man walks in a back alley in Vancouver’s downtown eastside, February 2019. More people fatally overdosed in British Columbia last year compared with 2017 despite efforts to combat the province’s public health emergency.
THE CANADIAN PRESS/Jonathan Hayward
A policy response focused on reducing prescription opioids will not resolve North America's opioid crisis. And it is hurting many adults who live with otherwise unbearable chronic pain.
Lawsuits against Purdue say its drug Oxycontin played a key role in the opioid epidemic.
The $270 million settlement may not mean a whole lot if Purdue files for bankruptcy as it's reportedly considering.
Anti-opioid protest at the Harvard Art Museums, which the Sackler family has supported with charitable gifts.
There are limits to what charities can do now about past donors who are accused of morally reprehensible behavior.
Purdue faces about 2,000 lawsuits related to the opioid crisis.
AP Photo/Toby Talbot
OxyContin maker Purdue has reportedly been mulling a bankruptcy filling, just as the first of around 2,000 lawsuits against it prepares to go to trial.
What is each partner looking to get?
The interests of pharmaceutical companies and public health are not the same. Industry dollars can distort research agendas, while framing health challenges and solutions in ways that benefit corporations.
Classified advertisement for Leslie Keeley’s Gold Cure.
ProQuest Historical Newspapers: Chicago Tribune, July 21, 1884
Considered in historical context, Purdue's plan to peddle opioid addiction medicines to vulnerable people is not so surprising. Gilded-Age pharmaceutical companies used similar strategies.